Alerta

Process for preparing dispensable testosterone cream

Resumen de: AU2024276494A1

This invention relates to a process of preparing an oil-in-water emulsion comprising testosterone for use in a pump-action dispensing device. It further relates to the oil-in-water emulsion produced by the process of the invention, and the combination of the emulsion with a pump-action dispensing device.

Lipids for use in lipid nanoparticle formulations

Resumen de: MX2025013218A

Compounds are provided having the following Structure (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R¹, R¹, L¹, L², L^2a, L^2b, and A are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

Corticosteroid nanosuspensions and uses thereof

Resumen de: MX2025013065A

Suspension formulations of nanoparticles of clobetasol propionate are described. The suspensions can be used therapeutically to treat skin and ocular burns; to enhance wound healing; to prevent or reduce hypertrophic scarring/keloids; to treat allergic rhinitis/sinusitis, asthma, inner ear disorders including hearing loss, tinnitus, or vertigo, tenosynovitis, tendinitis, enthesitis or arthritis.

Coronavirus vaccine

Resumen de: ZA202406805B

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

RIBOSE-MODIFIED CAP ANALOG AND USE THEREOF

Resumen de: ZA202502361B

The present disclosure provides a ribose-modified cap analog and a use thereof, and belongs to the technical field of chemical and biological engineering. The ribose-modified cap analog has a structure of formula (I). The ribose-modified cap analog described herein can improve the stability of mRNA and/or the translation efficiency of mRNA.

CONTROLLED RELEASE OF IMMUNOSUPPRESSANTS FROM SYNTHETIC NANOCARRIERS

Resumen de: CA3251686A1

Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.

ＣＡＲ ｍＲＮＡ送達のための脂質ナノ粒子とその製剤

Resumen de: US2022378700A1

The present invention relates to lipid nanoparticles (LNP) or compositions thereof for delivery of mRNA molecules encoding CAR, nucleic acid molecule, and/or therapeutic agents to selected targets, such as cells. Thus, in various aspects, the present invention also provides methods of preventing or treating diseases or disorders in a subject in need thereof using the said LNPs or compositions thereof.

イオン化脂質およびそれを含む脂質ナノ粒子

Resumen de: CN120225501A

The present invention provides an ionizable lipid of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer of any of them; a lipid nanoparticle comprising the ionizable lipid (in particular as an encapsulant), optionally comprising a pharmaceutically active agent; and a pharmaceutical composition comprising the lipid nanoparticles. The present invention also provides a lipid nanoparticle for a drug or a pharmaceutical composition comprising the same, and a use of the lipid nanoparticle as an encapsulant. # imgabs0 #

核酸送達のための新規脂質及び脂質ナノ粒子組成物

Resumen de: AU2023383821A1

Provided are cationic lipid compounds represented by formula (I), which can be applied to lipid nanoparticles such that the lipid nanoparticles can target different tissue organs for drug delivery. The cationic lipid compounds or a lipid nanoparticle composition comprising same can specifically deliver a preventive/therapeutic agent, especially a nucleic acid component, to a target organ.

メッセンジャーＲＮＡの乾燥粉末製剤の組成物及びその使用方法

Resumen de: CN120265279A

The present disclosure provides stable dry powder messenger RNA formulations for therapeutic use and methods of making and using the same.

カチオン性脂質及びその製造方法

Resumen de: CN120129674A

The present invention relates to a cationic lipid and a method for preparing the same, and more particularly, to a cationic lipid which promotes the formation of a complex with an anionic drug material so as to be useful for drug delivery, and a method for preparing the cationic lipid.

阻害性核酸およびその使用方法

Resumen de: CN120359038A

The present disclosure provides inhibitory nucleic acids, compositions comprising the inhibitory nucleic acids, and methods of using the inhibitory nucleic acids to treat various diseases.

核酸の送達用のイオン化可能な脂質および脂質ナノ粒子組成物

Resumen de: MX2025005703A

Novel ionizable lipids are provided. Also provided are novel lipid nanoparticle compositions for the delivery of nucleic acid material to cells in vitro and in vivo with different and improved pharmacokinetic profiles as compared to what is typically observed in the art. Also provided are methods for using the compositions in research and as therapeutics.

トランスポーターペプチド及びその使用

Resumen de: CN120225539A

The present invention relates to a transporter peptide capable of binding to a transferrin receptor. The transporter peptide can be covalently or non-covalently conjugated with an effector to form a transporter peptide conjugate, or the transporter peptide and an effector form a recombinant transporter peptide conjugate in a manner that represents a nucleic acid encoding the transporter peptide and the effector. The transporter peptide and the recombinant transporter peptide transport the effector to a target by binding to a transferrin receptor. Binding of the transporter peptide to a transferrin receptor on a cell of a tissue barrier induces transendocytosis of the cell to transport the transporter peptide conjugate through the tissue barrier. The transport peptide can be used as a drug delivery system and can be used for related treatment of central nervous system (CNS) diseases.

口蹄疫ウィルス様粒子またはナノ粒子生産のための組換え発現ベクターおよびこれを用いたワクチン組成物

Resumen de: WO2024112115A1

The present invention relates to a recombinant expression vector for preparing foot-and-mouth disease virus-like particles or nanoparticles, and a vaccine composition using same. The present invention provides virus-like particles or nanoparticles, and a preparation method therefor, the particles or nanoparticles being produced by expressing, simultaneously, VP4 with VP1, VP2 and VP3 or expressing VP1, VP2 and VP3 while excluding VP4, from among FMDV structural proteins. The virus-like particles or nanoparticles, prepared according to the method of the present invention, can be effectively used in the prevention of diseases caused by foot-and-mouth disease viral infection.

イオン化脂質及びその応用

Resumen de: CN118125994A

The present invention provides an ionizable lipid, and a drug delivery system comprising the ionizable lipid. Specifically, the invention provides an ionizable lipid with a structure as shown in a formula (I), or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. The lipid nanoparticles constructed by using the ionizable lipid can realize safe and efficient delivery of nucleic acid drugs, small molecule drugs, peptide drugs and protein drugs. # imgabs0 #

双脂质结构

Resumen de: TW202438044A

A compound having the following structure of Formula (I): or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, R4, R5, R6, G1, G2, x, y, n, z, and w are as defined herein. Compositions comprising the compounds, and their use in methods of treating diseases, are also described.

一种胡柚皮外泌体载药靶向制剂及其制备方法和应用

Resumen de: CN121015596A

本发明公开了一种胡柚皮外泌体载药靶向制剂及其制备方法和应用，属于生物医药技术领域。该制备方法具体包括以下步骤：(1)将胡柚皮进行组织破碎，高速离心除去破碎组织及细胞，超高速离心收集外泌体粗提物，利用蔗糖密度梯度离心纯化胡柚皮外泌体；(2)将川陈皮素溶于乙醇，将胡柚皮外泌体溶于磷酸盐缓冲液，混合，搅拌，利用蔗糖密度梯度离心分离负载川陈皮素胡柚皮外泌体；(3)重悬于磷酸盐缓冲液，冷冻干燥，即得。本发明利用胡柚外泌体的抗炎作用，以及胡柚外泌体内质网定位提高川陈皮素靶向抑制STING通路治疗炎症作用，通过吸入给药治疗肺炎。

一种共递送铜离子和铜离子螯合前药的纳米药物组合物及其制备方法和用途

Resumen de: CN121015593A

本发明提供了一种共递送铜离子和铜离子螯合前药的纳米药物组合物及其制备方法和用途。本发明所述纳米药物组合物通过使用含邻苯二酚结构的多酚对二价铜盐中的铜离子和铜离子螯合前药进行负载，并与苯硼酸修饰的透明质酸组装形成纳米粒而得到。本发明所述纳米药物组合物解决了铜离子和铜离子螯合前药共递送的问题，有助于在肿瘤微环境氧化条件下，选择性地触发高细胞毒性的8‑羟基喹啉铜络合物的生成，实现高效低毒的抗肿瘤策略。此外，本发明所述纳米药物组合物使用溶剂交换法制备，制备操作简单，条件温和。

用于PCSK9基因修饰或编辑的组合物及其使用方法

Resumen de: WO2025180418A1

Provided are a composition for PCSK9 gene modification or editing, and a method for using same. Specifically, provided is a composition for editing a PCSK9 gene target, comprising a base editor for carrying out base editing on a PCSK9 gene target, and a guide RNA. The composition can effectively edit a target gene, and can be used for treating diseases caused by the abnormality of a polynucleotide which codes a PCSK9 protein.

一种基于花青素包覆的纳米粒子的制备方法及其应用

Resumen de: CN121015626A

本发明公开了一种基于花青素包覆的纳米粒子的制备方法及其应用，首先从蓝靛果中提取花青素以及细胞外囊泡（EVs），得到花青素粉末；然后向得到的花青素粉末中加入PBS、角鲨烯，得到角鲨烯@花青素；再将EVs加入到角鲨烯@花青素中，共孵育后离心处理，得到花青素包覆的纳米粒子。该纳米粒子具有粒径为180~220nm、Zeta电位为‑45~‑55mV、包封率≥85%的特征，稳定性与生物相容性优异，具有调节肠道菌群、抗抑郁、抗氧化、抗炎等功能，且生物相容性好、毒性低，解决了其稳定性和生物利用度问题，实现了对肠道菌群的精准调控，为抑郁症治疗提供了一种安全高效的新途径。

一种基于分步酶解的防脱植物组合物及其制备方法

Resumen de: CN121015734A

本发明涉及防脱技术领域，具体涉及一种基于分步酶解的防脱植物组合物及其制备方法。该组合物由芍药提取物、侧柏叶提取物经丝素蛋白纳米粒负载而成，其中芍药提取物采用纤维素酶与果胶酶分步酶解工艺制备，与侧柏叶提取物按特定比例复配后，通过丝素蛋白纳米粒实现高效包载与缓释。实验验证表明，该组合物在5α还原酶抑制、人毛乳头细胞增殖及ALPL、TGF‑β基因表达调控方面具有协同增效作用，防脱效果显著优于单一成分及传统提取工艺制备的组合物。本发明通过工艺创新与配方优化，解决了现有防脱植物制剂功效单一、透皮吸收差的问题。

一种用于治疗炎症性肠病的多功能化硒纳米粒及其制备方法和应用

Resumen de: CN121015594A

本发明公开了一种用于治疗炎症性肠病的多功能化硒纳米粒及其制备方法和应用，涉及生物医药技术领域。该多功能化硒纳米粒为核‑壳结构，包括内核和包覆所述内核的外层；该内核为硒纳米粒；该外层为嵌入壳寡糖的聚多巴胺外壳。本发明提供的多功能化硒纳米粒具有良好的稳定性与分散性，能够靶向肠道炎症部位，延长纳米粒在体时间，在细胞、动物层面显示出强大的抗氧化和抗炎活性。纳米粒整体基于天然材料的低毒性和结肠靶向性，较传统糖皮质激素/生物制剂安全性更高，通过调节氧化还原稳态、延长药物作用时间等方式减轻肠道炎症，有望成为兼具高效性、靶向性和安全性的结肠炎治疗新策略。

一种氧化还原响应的载HE4 siRNA纳米粒、其制备方法及在治疗顺铂耐药卵巢癌的应用

Resumen de: CN121015597A

本发明提供一种氧化还原响应的载HE4siRNA纳米粒，该纳米粒由氧化还原响应的肿瘤靶向载体材料和HE4siRNA组成。氧化还原响应的肿瘤靶向载体材料为c(RGDfK)肽修饰的聚(乙烯亚胺)‑双硒键‑聚(乙二醇)(PEI‑SeSe‑PEG)。该纳米粒将载体材料和siRNA按N/P比为10:1混合，自组装成纳米粒，粒径在116nm左右，体外释放具有氧化还原响应性，在高浓度谷胱甘肽(GSH)的肿瘤微环境实现siRNA的释放，有利于在肿瘤部位发挥作用。本发明制备的氧化还原响应的载HE4siRNA纳米粒，实现溶酶体逃逸，又具有肿瘤靶向性，可抑制顺铂耐药卵巢癌细胞的增殖、迁移和侵袭，且在动物体内具有良好的肿瘤靶向性、抗肿瘤活性和生物相容性。该纳米粒制备方法简单，抗癌效果显著，具有良好的应用价值和市场前景。

金属配位脂质化合物及其组合物和应用

Nº publicación: CN121021379A 28/11/2025

Solicitante:

浙江大学